Expert Opinion on Drug Discovery
August 8, 2022
Andrzej Pilc, Agata Machaczka, Paweł Kawalec et al.
20 citations
A new generation of antidepressant drugs is emerging that works faster and helps patients who do not respond to current treatments. Unlike standard antidepressants that take weeks to work, these compounds—including ketamine, psilocybin, and scopolamine—can produce rapid effects, often after a single dose, and their benefits outlast the drug's presence in the brain. Their mechanism involves enhancing AMPA receptor function and antagonizing mGlu2/3 receptors, pointing to a strong glutamatergic component. Based on accumulating preclinical and clinical data, new drug approvals are expected soon.
Expert Opinion on Drug Discovery
January 31, 2025
Aline Silva de Miranda, Eliana C B Toscano, Venugopal Reddy Venna et al.
2 citations
Understanding the multiple pathophysiological mechanisms involved in treatment-resistant depression (TRD) may improve treatment by enabling a more personalized approach. Esketamine has been approved for TRD, and novel drugs with rapid antidepressant actions, such as psilocybin and buprenorphine, are being investigated as potential therapies. Technological advances like omics approaches have expanded knowledge of the molecular and genetic underpinnings of TRD and could open new avenues for studying glial-mediated mechanisms, including their interactions with neurons, as therapeutic targets.
Expert Opinion on Drug Discovery
July 4, 2026
Christopher D. Verrico, Lynnette A. Averill, Cameron J Moore et al.
Ibogaine, a natural alkaloid, shows potential for treating substance use disorders, trauma, mood disorders, and suicidality, but clinical use is limited by safety concerns and regulatory barriers. Researchers are pursuing two main strategies: developing ibogaine-like compounds that keep broad effects while reducing risks, and creating selective 'bespoke' analogs targeting specific conditions like opioid use disorder, traumatic brain injury, or PTSD. The authors emphasize that the field should avoid oversimplified views that derivatives are uniformly better or interchangeable, and call for greater conceptual clarity and mechanistic humility as ibogaine-based therapies move toward regulated medical use.